As securities litigation continues to target biotechnology and life sciences companies at elevated levels, proactive legal planning has become an essential part of corporate governance. In a recent Law360 article, FBFK Law Partner Wesley Horton explains why litigation risk management should begin well before clinical setbacks, regulatory announcements, or market-moving events occur. The article examines how investor communications, disclosure practices, governance, and executive messaging can significantly influence a company’s ability to respond when challenges arise.
Horton also outlines practical strategies for reducing litigation exposure, including strengthening disclosure controls, coordinating communications across leadership teams, preserving key documents, and involving legal counsel early in the decision-making process. Rather than viewing litigation preparedness as a defensive measure, he emphasizes that thoughtful planning can help companies protect enterprise value, maintain investor confidence, and support continued innovation in an increasingly scrutinized industry.